Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02020538
Registration number
NCT02020538
Ethics application status
Date submitted
19/12/2013
Date registered
25/12/2013
Date last updated
22/04/2020
Titles & IDs
Public title
Limiting IV Chloride to Reduce AKI After Cardiac Surgery
Query!
Scientific title
Does Varying the Chloride Content of Intravenous Fluid Alter the Risk of Acute Kidney Injury After Cardiac Surgery?
Query!
Secondary ID [1]
0
0
382/13
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
LICRA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Patients Undergoing Cardiothoracic Surgery
0
0
Query!
Condition category
Condition code
Renal and Urogenital
0
0
0
0
Query!
Kidney disease
Query!
Injuries and Accidents
0
0
0
0
Query!
Other injuries and accidents
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Low-chloride perioperative intravenous fluid strategy
Other interventions - High-chloride perioperative intravenous fluid strategy
Placebo Comparator: Chloride-rich IV fluid - The chloride-rich strategy will include 0.9% saline as the perioperative crystalloid of choice with 4% albumin as the perioperative colloid of choice.
Active Comparator: Chloride-poor IV fluid - A low-chloride strategy of perioperative IV fluid will include PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice with 20% albumin as the colloid of choice.
Other interventions: Low-chloride perioperative intravenous fluid strategy
The low-chloride perioperative IV fluid strategy will include the use of PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice and 20% albumin as the colloid of choice.
Other interventions: High-chloride perioperative intravenous fluid strategy
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Peak ? serum creatinine
Query!
Assessment method [1]
0
0
Maximum change in serum creatinine from baseline
Query!
Timepoint [1]
0
0
5 days postoperatively
Query!
Primary outcome [2]
0
0
AKI =stage2
Query!
Assessment method [2]
0
0
AKI, =stage2, defined by creatinine-based KDIGO criteria
Query!
Timepoint [2]
0
0
5 days postoperatively
Query!
Secondary outcome [1]
0
0
Individual stages of AKI
Query!
Assessment method [1]
0
0
Individual stages of AKI, defined by creatinine-based KDIGO criteria
Query!
Timepoint [1]
0
0
7 days
Query!
Secondary outcome [2]
0
0
Mortality
Query!
Assessment method [2]
0
0
Mortality
Query!
Timepoint [2]
0
0
On discharge from hospital (7-30 days)
Query!
Secondary outcome [3]
0
0
Renal replacement therapy
Query!
Assessment method [3]
0
0
Renal replacement therapy
Query!
Timepoint [3]
0
0
On discharge from hospital (7-30 days)
Query!
Secondary outcome [4]
0
0
ICU Length of stay
Query!
Assessment method [4]
0
0
ICU Length of stay
Query!
Timepoint [4]
0
0
On discharge from hospital (7-30 days)
Query!
Secondary outcome [5]
0
0
Hospital Length of stay
Query!
Assessment method [5]
0
0
Hospital Length of stay
Query!
Timepoint [5]
0
0
On discharge from hospital (7-30 days)
Query!
Secondary outcome [6]
0
0
Time to first extubation
Query!
Assessment method [6]
0
0
Time to first extubation
Query!
Timepoint [6]
0
0
On discharge from hospital (7-30 days)
Query!
Secondary outcome [7]
0
0
Red cell transfusion requirement
Query!
Assessment method [7]
0
0
Volume of packed red blood cells transfused
Query!
Timepoint [7]
0
0
Intraoperative and postoperatively through completion of postoperative day 1 or ICU discharge, whichever occurred first
Query!
Secondary outcome [8]
0
0
Fresh frozen plasma transfusion requirement
Query!
Assessment method [8]
0
0
Volume of fresh frozen plasma transfused
Query!
Timepoint [8]
0
0
Intraoperative and postoperatively through completion of postoperative day 1 or ICU discharge, whichever occurred first
Query!
Secondary outcome [9]
0
0
Platelet transfusion requirement
Query!
Assessment method [9]
0
0
Volume of platelets transfused
Query!
Timepoint [9]
0
0
Intraoperative and postoperatively through completion of postoperative day 1 or ICU discharge, whichever occurred first
Query!
Secondary outcome [10]
0
0
Cryoprecipitate transfusion requirement
Query!
Assessment method [10]
0
0
Volume of cryoprecipitate transfused
Query!
Timepoint [10]
0
0
Intraoperative and postoperatively through completion of postoperative day 1 or ICU discharge, whichever occurred first
Query!
Eligibility
Key inclusion criteria
All adult patients undergoing surgery by Division of cardiothoracic surgery
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Nil
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
3/02/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
12/02/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1298
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Alfred Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3004 - Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Bayside Health
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
Australian and New Zealand College of Anaesthetists
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This primary aim of this study is to test the impact of a strategy of perioperative
chloride-restriction through intravenous (IV) fluid therapy on the incidence of acute kidney
injury after cardiac surgery.
A prospective, open-label, single-centre 4-period sequential study of varying strategies of
perioperative IV fluid composition will test the hypothesis that a perioperative protocol for
the administration of chloride-poor intravenous fluids compared to chloride-rich intravenous
fluids will reduce the incidence of AKI after adult cardiothoracic surgery.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02020538
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
David R McIlroy, MBBS, MClinEpi, FANZCA
Query!
Address
0
0
Alfred Hospital and Monash University
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02020538
Download to PDF